Compugen Ltd (CGEN) Stock Price, Quote & News

Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of P...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 765 8585

Fax: 972 3 765 8555

Website: cgen.com

Address:

Azrieli Center, Building D 26 Harokmim Street, Holon, Israel

AGC_Trader May. 1 at 1:45 PM

$CGEN did anyone else see the spike to $3.17 in PM?

0 · Reply

KoalaFlipper May. 1 at 1:16 PM

$CGEN todays price prob gonna be 2,80+

0 · Reply

Sobo90 May. 1 at 9:04 AM

$CGEN didnt insiders just sell? Maybe nothing or they dont expect good news for some time.

1 · Reply

KoalaFlipper Apr. 30 at 5:56 PM

$CGEN only 218k traded share average is 300k to 400k shares.

0 · Reply

KoalaFlipper Apr. 30 at 5:54 PM

$CGEN buy that shit!!

0 · Reply

KoalaFlipper Apr. 30 at 5:50 PM

$CGEN looks like someone took the dip and its back at the good run hopefully.

0 · Reply

zerodayrounder Apr. 29 at 3:46 PM

$CGEN that was a nasty suck in but still seems like CGEN has lots of valuable stuff/partnerships/unigen platform etc. But definitely a dirty suck in in the short term.

0 · Reply

TwitteringTom Apr. 29 at 2:14 PM

$CGEN the party over?

1 · Reply

SuperGreenToday Apr. 29 at 1:13 PM

$CGEN Share Price: $2.73 Contract Selected: Dec 18, 2026 $2.5 Calls Buy Zone: $0.50 – $0.61 Target Zone: $0.91 – $1.11 Potential Upside: 73% ROI Time to Expiration: 232 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

TwitteringTom Apr. 28 at 6:59 PM

$CGEN whats with the large DUMP

1 · Reply

Compugen Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 9, 2026, 7:00 AM EDT - 23 days ago

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference

Mar 9, 2026, 8:40 AM EDT - 7 weeks ago

Compugen Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 8:30 AM EST - 2 months ago

Compugen Earnings Call Transcript: Q4 2025

Mar 2, 2026, 7:00 AM EST - 2 months ago

Compugen Reports Fourth Quarter and Full Year 2025 Results

Feb 26, 2026, 2:00 PM EST - 2 months ago

Compugen Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 19, 2026, 7:00 AM EST - 2 months ago

Compugen to Participate in Upcoming Investor Conferences

Feb 17, 2026, 7:00 AM EST - 2 months ago

Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026

Feb 12, 2026, 7:00 AM EST - 2 months ago

Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors

Dec 17, 2025, 7:00 AM EST - 4 months ago

Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million

Nov 11, 2025, 3:20 PM EST - 6 months ago

Compugen Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 8:30 AM EST - 6 months ago

Compugen Earnings Call Transcript: Q3 2025

Nov 10, 2025, 7:00 AM EST - 6 months ago

Compugen Reports Third Quarter 2025 Results

Nov 4, 2025, 7:00 AM EST - 6 months ago

Compugen to Participate in Stifel 2025 Healthcare Conference

Oct 27, 2025, 7:00 AM EDT - 6 months ago

Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025

Oct 13, 2025, 7:00 AM EDT - 7 months ago

Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025

Oct 6, 2025, 7:00 AM EDT - 7 months ago

Compugen to Present at SITC 2025

Sep 16, 2025, 11:30 AM EDT - 8 months ago

Compugen Transcript: Q3 Investor Summit Group Virtual Conference 2025

Sep 8, 2025, 7:00 AM EDT - 8 months ago

Compugen to Present Research at the Single Cell Genomics 2025 Conference

Sep 5, 2025, 7:00 AM EDT - 8 months ago

Compugen Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 7:00 AM EDT - 8 months ago

Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 6, 2025, 8:30 AM EDT - 9 months ago

Compugen Earnings Call Transcript: Q2 2025

Aug 6, 2025, 7:00 AM EDT - 9 months ago

Compugen Reports Second Quarter 2025 Results

Jul 28, 2025, 7:00 AM EDT - 9 months ago

Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025

Jul 23, 2025, 7:00 AM EDT - 10 months ago

Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025

Jul 21, 2025, 7:00 AM EDT - 10 months ago

Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer

Jun 12, 2025, 7:00 AM EDT - 11 months ago

Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences

May 19, 2025, 8:30 AM EDT - 1 year ago

Compugen Earnings Call Transcript: Q1 2025

May 19, 2025, 7:00 AM EDT - 1 year ago

Compugen Reports First Quarter 2025 Results

May 13, 2025, 7:00 AM EDT - 1 year ago

Compugen Announces Leadership Transitions Effective September 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025

Apr 9, 2025, 12:00 PM EDT - 1 year ago

Compugen Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 7, 2025, 8:00 AM EDT - 1 year ago

Compugen Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 9:30 AM EDT - 1 year ago

Compugen Transcript: H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Conference

Mar 26, 2025, 7:00 AM EDT - 1 year ago

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Compugen Transcript: Leerink’s Global Healthcare Conference 2025

Mar 4, 2025, 8:30 AM EST - 1 year ago

Compugen Earnings Call Transcript: Q4 2024

Mar 4, 2025, 7:00 AM EST - 1 year ago

Compugen Reports Fourth Quarter and Full Year 2024 Results

Mar 3, 2025, 7:00 AM EST - 1 year ago

Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

Feb 26, 2025, 7:00 AM EST - 1 year ago

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

Feb 18, 2025, 7:00 AM EST - 1 year ago

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

Feb 11, 2025, 8:00 AM EST - 1 year ago

Compugen Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 4, 2025, 7:00 AM EST - 1 year ago

Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 8, 2025, 7:00 AM EST - 1 year ago

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

Nov 27, 2024, 7:00 AM EST - 1 year ago

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Nov 18, 2024, 8:35 AM EST - 1 year ago

Compugen Transcript: Stifel 2024 Healthcare Conference

Nov 12, 2024, 8:30 AM EST - 1 year ago

Compugen Earnings Call Transcript: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Compugen Reports Third Quarter 2024 Results

Nov 11, 2024, 7:00 AM EST - 1 year ago

Compugen to Participate in Stifel 2024 Healthcare Conference

Nov 5, 2024, 9:00 AM EST - 1 year ago

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present New Clinical Data at SITC 2024

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at Single Cell Genomics 2024 Conference

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Compugen Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 29, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 6, 2024, 8:30 AM EDT - 1 year ago

Compugen Earnings Call Transcript: Q2 2024

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Compugen Reports Second Quarter 2024 Results

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024

Jun 17, 2024, 7:00 AM EDT - 2 years ago

Compugen to Present at Upcoming Antibody Industrial Symposium

May 30, 2024, 7:00 AM EDT - 2 years ago

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

AZN

May 20, 2024, 8:30 AM EDT - 2 years ago

Compugen Earnings Call Transcript: Q1 2024

May 20, 2024, 7:00 AM EDT - 2 years ago

Compugen Reports First Quarter 2024 Results

May 16, 2024, 7:00 AM EDT - 2 years ago

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential

May 15, 2024, 7:00 AM EDT - 2 years ago

Compugen Appoints David Silberman as Chief Financial Officer

May 6, 2024, 7:00 AM EDT - 2 years ago

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024

Apr 25, 2024, 7:00 AM EDT - 2 years ago

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Compugen Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 10, 2024, 7:00 AM EDT - 2 years ago

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

Apr 3, 2024, 7:00 AM EDT - 2 years ago

Compugen to Participate in Two Upcoming Investor Conferences

Mar 11, 2024, 11:20 AM EDT - 2 years ago

Compugen Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 11, 2024, 7:00 AM EDT - 2 years ago

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy

Mar 6, 2024, 7:00 AM EST - 2 years ago

Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024

AGC_Trader May. 1 at 1:45 PM

$CGEN did anyone else see the spike to $3.17 in PM?

0 · Reply

KoalaFlipper May. 1 at 1:16 PM

$CGEN todays price prob gonna be 2,80+

0 · Reply

Sobo90 May. 1 at 9:04 AM

$CGEN didnt insiders just sell? Maybe nothing or they dont expect good news for some time.

1 · Reply

KoalaFlipper Apr. 30 at 5:56 PM

$CGEN only 218k traded share average is 300k to 400k shares.

0 · Reply

KoalaFlipper Apr. 30 at 5:54 PM

$CGEN buy that shit!!

0 · Reply

KoalaFlipper Apr. 30 at 5:50 PM

$CGEN looks like someone took the dip and its back at the good run hopefully.

0 · Reply

zerodayrounder Apr. 29 at 3:46 PM

$CGEN that was a nasty suck in but still seems like CGEN has lots of valuable stuff/partnerships/unigen platform etc. But definitely a dirty suck in in the short term.

0 · Reply

TwitteringTom Apr. 29 at 2:14 PM

$CGEN the party over?

1 · Reply

SuperGreenToday Apr. 29 at 1:13 PM

0 · Reply

TwitteringTom Apr. 28 at 6:59 PM

$CGEN whats with the large DUMP

1 · Reply

Otus Apr. 28 at 6:25 PM

$CGEN I’d expect buyers to start coming in. I know I’m one of them.

1 · Reply

zerodayrounder Apr. 28 at 3:50 PM

$CGEN pretty nasty breakout rejection

0 · Reply

alexpitti Apr. 28 at 3:01 AM

meeting ceo of $CGEN tomorrow

2 · Reply

TwitteringTom Apr. 27 at 5:52 PM

$CGEN whats this trash

0 · Reply

KoalaFlipper Apr. 26 at 6:52 PM

$CGEN just remember friday there was traded 1.4M shares normally there only gets traded 322K share. so something is happening very soon..

1 · Reply

JasperGreen Apr. 26 at 5:15 PM

$CGEN 4-6$ next?

1 · Reply

red75 Apr. 25 at 1:14 PM

$CGEN added on watch list

1 · Reply

InItToWinIt100 Apr. 24 at 8:57 PM

$CGEN Beautiful breakout of this consolidation over the last week and a half! https://www.trade-ideas.com/share.php?code=4QE7uaSj0L6FEb9UvpxUW6XqZY3BwkK7 `

0 · Reply

BeeDecay Apr. 24 at 5:16 PM

$CGEN

0 · Reply

Ghrr Apr. 24 at 3:55 PM

$CGEN Hit a new 52 week high at $3.23. Should be over $4.X post ER

0 · Reply

BRK_1 Apr. 24 at 2:09 PM

$CGEN we are not even 1 hour into the trading and volume is above avg, price is the highest in 4 years, whatever brewing behind the scenes is probably massive

1 · Reply

AGC_Trader Apr. 24 at 1:56 PM

$CGEN Everytime is the same: when I don't average down, the stock surges; when I do, the stock plummets...guess what I did with this 😅

0 · Reply

Market Cap	256.24M
Revenue (ttm)	72.76M
Net Income (ttm)	35.34M
EPS (ttm)	N/A
PE Ratio	7.19
Forward PE	N/A
Profit Margin	48.57%
Debt to Equity Ratio	0.00

Volume	426,300
Avg Vol	411,006
Day's Range	N/A - N/A
Shares Out	94.55M
Stochastic %K	24%
Beta	2.79
Analysts	Strong Sell
Price Target	$5.83